Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis

Stahlie, E.H.A.; Mulder, E.E.A.P.; Reijers, S.; Balduzzi, S.; Zuur, C.L.; Klop, W.M.C.; ... ; Akkooi, A.C.J.V. (2022)

Article / Letter to editor

Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of T-VEC. Of 341 publications that were identified, eight studies with a total of 642 patients were included. In patients with stage IIIB-IVM1a, the pooled complete-and overall response rate (CRR and ORR) were 41% and 64%, respectively. In patients with stage IIIB-IVM1c, the pooled CRR and ORR were 30% and 44%, respectively. In patients with stage IVM1b and IVM1c, the pooled CRR and ORR were 4% and 9%, respectively. Adverse events (AEs) were seen in 41-100% of all patients and 0-11% of AEs were severe. In conclusion, single agent T-VEC achieves the highest response rates in patients with early metastatic melanoma and is well-tolerated with generally only mild toxicities.

• Melanoma
• Immunotherapy
• T-VEC
• Metastatic

• All authors: Stahlie, E.H.A.; Mulder, E.E.A.P.; Reijers, S.; Balduzzi, S.; Zuur, C.L.; Klop, W.M.C.; Hiel, B. van der; Wiel, B.A. van de; Wouters, M.W.J.M.; Schrage, Y.M.; Houdt, W.J.V.; Grunhagen, D.J.; Akkooi, A.C.J.V.
• Date: 2022-07-01
• Journal: Critical Reviews in Oncology/Hematology
• Volume: 175
• DOI: doi:10.1016/j.critrevonc.2022.103705